Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this presentation, including statements regarding 23andMe's strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also 8-K filed with the Securities and Exchange Commission ("SEC") on June 21, 2021 and in 23andMe's Current Report on Form 10-Q filed with the SEC on August 13, 2021, as well as other filings made by 23andMe with the SEC from time to time. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Use of Non-GAAP Financial Measures

To supplement the 23andMe's unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that 23andMe defines as net income before net interest expense (income), net other expense (income), changes in fair value of warrant liabilities, depreciation and amortization of fixed assets, amortization of internal use software, non-cash stock-based compensation expense, acquisition-related costs, and expenses related to restructuring and other charges, if applicable for the period. 23andMe has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Adjusted EBITDA is a key measure used by 23andMe's management and the board of directors to understand and evaluate operating performance and trends, to prepare and approve 23andMe's annual budget and to develop short- and long-term operating plans. 23andMe believes Adjusted EBITDA is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods. Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23andMe's core operating performance. In particular, 23andMe believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of 23andMe's business. Accordingly, 23andMe believes that Adjusted EBITDA provides useful information in understanding and evaluating operating results in the same manner as 23andMe's management and board of directors.

In evaluating Adjusted EBITDA, you should be aware that in the future 23andMe will incur expenses similar to the adjustments in this presentation. 23andMe's presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. When evaluating 23andMe's performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results.

Intellectual Property

All rights to the trademarks, copyrights, logos and other intellectual property listed herein belong to their respective owners 23andMe’s use thereof does not imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, trademarks and trade names referred to in this Presentation may appear with the ® or ™ symbols, but such references are not intended to indicate, in any way, that such names and logos are trademarks or registered trademarks of 23andMe.

Industry and Market Data

This Presentation relies on and refers to certain information and statistics based on 23andMe's management's estimates, and/or obtained from third party sources which it believes to be reliable. 23andMe has not independently verified the accuracy or completeness of any such third party information.
Behind Every Data Point Is A Human Being
Our Mission is to Help People **Access, Understand** and **Benefit** from the **Human Genome**

Size and scale of 23andMe enables rapid, novel discoveries

1As of September 30, 2021.
The Healthcare System is Dysfunctional

“Of course our system isn’t about healthcare, it’s about maximizing revenue for a whole bunch of different players that have nothing to do with what’s good for patients.”

Elisabeth Rosenthal (Editor-in-Chief, Kaiser Health News)

25% 1
U.S. healthcare spending is waste

75% 2
Consumers wish their healthcare experience was more personalized

-15 3
The net positive score Americans gave the pharmaceutical industry

<12% 4
Probability of success for a drug to be approved, taking ~10 years and costing $2.6B to develop

### Consumer Scale and Empowerment is the Key to Disrupting Healthcare

<table>
<thead>
<tr>
<th>Media</th>
<th>YouTube</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commerce</td>
<td>Amazon</td>
</tr>
<tr>
<td>Transportation</td>
<td>Uber</td>
</tr>
<tr>
<td>Hospitality</td>
<td>Airbnb</td>
</tr>
<tr>
<td>Healthcare</td>
<td>23andMe</td>
</tr>
</tbody>
</table>

“Healthcare cannot change from within, it will need an outside force to change it, and that force will be our customers.”

Anne Wojcicki
We Pioneered Digital DTC Healthcare to Empower Customers With Affordable, Direct Access

1. The Retail DNA Test
By Anita Hamilton | Wednesday, Oct. 29, 2008

Best Inventions of 2008

Proven accuracy (99% NPV/PPV) and accessibility¹

- 2015 Carrier Status (inherited conditions)
- 2016 GHR (genetic health risk)
- 2017 BRCA (breast and ovarian cancer)
- 2018 PGt (pharmacogenetic metabolism)
- 2019 MUTYH (colorectal cancer)
- 2020 PGt (pharmacogenetic drug response)
- 2021 HOXB13 (prostate cancer)

¹ See FDA De Novo Authorizations 149944, 160026, 170046 and 180028 and FDA 510K Clearances K182784 and K193492.
Providing Customers With Key, Actionable Insights

“Like me, there are many women who have slipped through the cracks of our current medical screening system, either because they don’t have a family history of breast or ovarian cancer. Or they do not know that they have Ashkenazi Jewish ancestry. In my case, even though I know I have Ashkenazi ancestry, that wasn’t enough to prompt my doctor to consider screening. So there are many women walking around with this risk, who, like me, would have never known of their own risk but for this test from 23andMe.”

23andMe customer who discovered she had a BRCA1 mutation

80% Customers receive a report with a meaningful genetic variant

12,000+ Customers with an increased risk for Chronic Kidney Disease

7,000+ Customers with a tested BRCA1 / BRCA2 variant

9,000+ Customers with Hypercholesterolemia (FH) variants

Note: Estimates based on penetrance of variants in 23andMe’s Database.
Transforming Healthcare With 23andMe’s Crowdsourced, Genetic Database

“The mission of 23andMe is not just about genetics. We want to transform healthcare...What I have learned after 11 years is that people want to participate in research...They don’t want to be a human subject. They want to be respected as an equal and as a partner in the process.”

Anne Wojcicki to Recode Decode (2018)
Unlocking the Genetic Code Creates the Opportunity to Revolutionize the Diagnosis, Prevention and Treatment of Most, if Not All, Human Disease

Cracking the code...

...is a data problem, a very big data problem

We are all 99.5% genetically alike

3 billion base pairs long
We Are Redefining Healthcare. With Data. At Scale.

Cumulative Genotyped Customers
(in M, fiscal year ends March 31)

10M+ Genetic Profiles
Created Critical Mass

Empowering Consumers
11.9M
Genotyped Customers¹

Enabling Research & Services
4B+
Phenotypic Data Points¹

Developing Therapeutics
40+
Program²

¹As of September 30, 2021.
²As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets.
Consumer Powered Healthcare Flywheel

We run hundreds of billions of association tests per year that further our unique understanding of human biology.

11.9M
Genotyped Customers

80%
Opt-In to Research

 Phenotypic Data

Genetic Data

Insights

Innovative Results Return Value to the Customer

1As of September 30, 2021. 2As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets.
Our Ancestry Service
A Mass Entry Point to Building a Revolutionary Database

Ancestry Composition

DNA Relatives

Visualize Genetic Connections With an Automatically Built Family Tree

Note: Opt-in required for DNA Relatives and Family Tree builder.
How Ancestry Matters In Connection To Your Health

Ann M.
23andMe Customer

Ann did not know her ancestry origins and would not have been eligible for clinical testing under current guidelines.

Ann decided to do 23andMe to learn more about her potential health risks. Based on her 23andMe report, she discovered she had a BRCA1 mutation.

Her doctor confirmed the results and she opted to have surgeries to reduce her risk of having ovarian and/or breast cancer.

Current clinical guidelines and eligibility for insurance coverage limit BRCA testing to women with a personal or family history of cancer (Robson, 2003)

DTC Testing

---

1 NCCN is the National Comprehensive Cancer Network® (NCCN®).
**Our Health Service**

The First and Only Multi-Disease DTC Genetic Service That Includes FDA-Authorized Reports and Provides Personalized Genetic Insights and Tools

### Health Predispositions

30+

Including:
- Type 2 Diabetes (Powered by 23andMe Research)
- Coronary Artery Disease
- Uterine Fibroids
- Migraine
- MUTYH-Associated Polyposis
- BRCA1/BRCA2 (selected variants)
- HOXB13 (prostate cancer)

### Wellness

10

Including:
- Muscle Composition
- Genetic Weight
- Alcohol Flush Reaction
- Saturated Fat and Weight
- Sleep Movement
- Dog & Cat Allergies

### Carrier Status

40+

Including:
- Cystic Fibrosis
- Sickle Cell Anemia
- Familial Hyperinsulinism (ABCC8-Related)
- Tay-Sachs Disease
- Glycogen Storage Disease (Type 1a)

### Pharmacogenetics

3

Including:
- SLCO1B1 Drug Transport
- CYP2C19 Drug Metabolism
- DPYD Drug Metabolism
  - e.g., citalopram and clopidogrel

---

1 Wellness information does not require FDA Authorization.

---
A Meaningful, Engaging (and Fun) Experience

Strong Engagement and Trust Drive Longitudinal Data Collection

~80% customers consent to research

4B+ phenotypic data points

180+ published research papers

56% of people with results like yours prefer chocolate ice cream.

Hey Jaime,
You have more Neanderthal DNA than 78% of other customers.

Neanderthals were prehistoric humans who interbred with modern humans before disappearing around 40,000 years ago.
Subscription is the Next Phase of Our D2C Journey

Pharmacogenetics
3 reports (FDA-Authorized)

Heart Health Reports
Atrial Fibrillation, Coronary Artery Disease, LDL Cholesterol, Hypertension

DNA Relatives
Advanced filters, access up to 5,000 relatives

Polygenic Risk Scores (Powered by 23andMe Research)
Rapidly discovering new genetic insights:
- Cancer risk
- Reproductive Health
- Diet
- Sleep
- Fitness and injuries
- Migraines

125K+ subscribers as of March 2021
Soft Launch October 2020
Genetic Data Helps Drive Behavior Change

76% Report taking a positive health action¹

- Eat healthier: 55%
- Set future goals to be healthier: 51%
- Adopt a healthier lifestyle in general: 50%
- Exercise more: 45%
- Get more rest / sleep: 42%
- Stop drinking / drink less: 16%
- Stop smoking / smoke less: 7%

¹ Based on 2019 online survey, designed by 23andMe and M/A/R/C Research, of 1,046 23andMe Health + Ancestry customers.
Opportunity for Personalized Healthcare at Scale

Practice of Medicine Today
Reactive – no customization until symptomatic

23andMe+™
Proactive – truly individualized from the very beginning
Genetics-Based Approach Will Transform the Continuum of Care

70% Providers think genetic tests will improve clinical outcomes¹

1 Health Affairs, "Views Of Primary Care Providers On Testing Patients For Genetic Risks For Common Chronic Diseases." (2018).
By leveraging Lemonaid Health’s online digital health platform, we can deliver personalized, proactive, genetically-based healthcare at scale.
Lemonaid Health’s Comprehensive Digital Health Services

Complement 23andMe’s Personalized Health Platform

- Reputable online medical team of physicians and nurse practitioners serving patients in all 50 states
- Lab-ordered tests with results provided via secure online account
- Custom-built electronic medical records (EMR) platform designed from ground up for modern telehealth

![Diagram]

Online doctor visits
- cutting out the doctor waiting room – with fully integrated w-2 core clinical team

Mail order pharmacy
- cutting out the retail pharmacy – owned and controlled mail order pharmacy

Most broad range of services
- building the online healthcare brand with the biggest impact

All connected using an algorithm driven proprietary technology platform
Transforming Therapeutic Development With the 23andMe Database
Drug Development is Inefficient

Limited Use of Data and Lack of Patient Engagement Constrain Productivity

- 7 years average time-to-IND\(^1\)
- ~90% failure rate\(^2,3\)
- $2.6B average cost of drug development\(^3\)

---


\(^2\) Probability of success for a drug to be approved is estimated to be <12%. \(^3\) PhRMA, “Biopharmaceutical Research & Development: The Process Behind New Medicines” (2015).
The support of human genetic evidence for approved drug indications

Nelson et. al 2015

---

2 Probability of success for a drug to be approved is estimated to be <12%. PhRMA, “Biopharmaceutical Research & Development: The Process Behind New Medicines” (2015).
Our Scale Enables Real-Time Genetics Health Research¹

| Condition                  | Count  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>High cholesterol</td>
<td>1,876,573</td>
</tr>
<tr>
<td>Type 2 Diabetes</td>
<td>358,275</td>
</tr>
<tr>
<td>Type 1 Diabetes</td>
<td>37,853</td>
</tr>
<tr>
<td>Depression</td>
<td>1,785,456</td>
</tr>
<tr>
<td>APOE e4 carriers (Alzheimer's risk)</td>
<td>2,355,068</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>85,604</td>
</tr>
<tr>
<td>Asthma</td>
<td>1,113,057</td>
</tr>
<tr>
<td>Eczema</td>
<td>667,019</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>250,764</td>
</tr>
<tr>
<td>Irritable Bowel</td>
<td>634,734</td>
</tr>
<tr>
<td>UC / Crohn's</td>
<td>107,126</td>
</tr>
<tr>
<td>Barrett's Esophagus</td>
<td>64,800</td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>534,696</td>
</tr>
<tr>
<td>Coronary Artery</td>
<td>159,135</td>
</tr>
<tr>
<td>Pulmonary Embolism</td>
<td>42,836</td>
</tr>
<tr>
<td>Systemic Sclerosis</td>
<td>9,047</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>7,334</td>
</tr>
<tr>
<td>Idiopathic Pulmonary Fibrosis</td>
<td>4,528</td>
</tr>
</tbody>
</table>

1,287,060² COVID-19 study participants

750K Consumers participated in the COVID-19 study in the first 90 days

(As of January 2021)

COVID-19 Research (2020)

- March 16: Kicked Off Study
- April 6: Launched Study
- June 8: Preliminary Findings
- Sept. 7: Posted Findings³

GWAS is a statistical analysis of Single Nucleotide Polymorphisms (SNPs), looking to identify differences in frequency between disease cases and controls.

SNPs linked with disease will be found at different frequencies in cases versus controls.

Association is represented by the level of statistical significance (p-value) of the SNP frequency difference.

SNPs can be tested across the genome and mapped to specific regions.
Example: Number of Osteoarthritis GWAS¹ hits dramatically increase as database grows

New programs are identified through GWAS¹ hits, which increase as size of database grows

¹ Genome-Wide Association Study.
Hundreds of Distinct Clinical Phenotypes Across Major and Rare Diseases

Phenotype: NAFLD (Non-Alcoholic Fatty Liver Disease)
Cases: 48048
Controls: 251744
Hits: 104
New Lost: 44
Lost: 2
10,000's of Genome-Wide Association Study (GWAS) Hits

Determine Disease Associated Genes and Directionality

Researching to Understand Compelling Biology

Identifying Druggable Proteins

Phenome-Wide Association Studies (PheWAS) Reveal Additional Indications and Potential Safety Concerns

Assessment of Unmet Need and Competitive Landscape

Best Drug Targets

Wet lab validated targets progress through standard stages of research toward the selection of preclinical lead molecules and clinical development

23andMe's database yields thousands of GWAS hits

Advanced biology and medicinal chemistry guide design of optimal compounds from initial targets

Phenotypic breadth provides unique ability to uncover potential safety issues or possible indication expansions
Genetic Association of the TSLP Signalling Pathway With Asthma

TSLP is a well-known cytokine with a role in maintaining immune homeostasis and regulating inflammatory responses at mucosal barriers.

The TSLP signaling pathway is an attractive therapeutic target. e.g. Tezepelumab, a TSLP-blocking monoclonal antibody for treatment of asthma.

Our genetic data shows that multiple genes within the TSLP pathway associate strongly with asthma.
Breadth of Phenotyping Provides Deeper Genetic Understanding Beyond Single Diseases

- PheWAS = Phenotype Wide Association Study
- Every SNP in the genome can be interrogated at >1,000 medically related phenotypes.
- Besides the role of a gene in a disease of interest, we can use genetics to learn potential indication expansions or possible unwanted toxicities.
- For TSLP, PheWAS indicates lack of effect in eczema but also highlights potential indication expansion in a rare disease.
“Our work with 23andMe is exceeding expectations and helping us advance a new way of thinking about drug discovery, one driven by genetics and the DNA we inherit. The insights of why some people are protected from or are at greater risk for certain diseases can lead to genetically validated targets that are at least twice as successful in clinical trials.”

Dr. Hal Barron, Chief Scientific Officer & President R&D, GSK (2021)
We Have Generated a Deep Pipeline Across Multiple Therapeutic Areas

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Programs</th>
<th>Next Milestone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preclinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Next Milestone</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EARLY-STAGE THERAPEUTIC AREAS</strong></td>
<td>(multiple programs in each area)</td>
<td></td>
</tr>
<tr>
<td>Immuno-oncology</td>
<td>GSK’608</td>
<td>Phase 1 Data</td>
</tr>
<tr>
<td></td>
<td>(CD96)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>23ME’610</td>
<td>23andMe</td>
</tr>
<tr>
<td></td>
<td>(CD200R1)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular/ Metabolic</td>
<td></td>
<td>Phase 1 Data</td>
</tr>
<tr>
<td>Immunology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurology</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Our Lead CD96 Program Was Identified With ML and AI Applied to Our Proprietary I/O Genetic Signature

Large I/O market with over $41B expected in 2021 sales

2021 projected sales of leading checkpoint inhibitors

KEYTRUDA  $17.0B

OPDIVO  $7.9B

YERVOY  $1.8B

CD96 pathway validated with ML and AI applied to our proprietary I/O genetic signature which also identifies marketed I/O drugs

I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes

We discovered the signaling pathway has a similar genetic I/O signature

CD96 plays an important role in regulating NK and T cell antitumor activity

GSK’608 (anti-CD96) is progressing through a Phase 1 multi-ascending dose trial in patients with advanced solid tumors

Source: Evaluate Pharma historical and forecast estimates.
GSK'608 Targeting CD96: A Novel Genetically-Validated Approach to Anti-Cancer Therapy

- CD226 is an NK/T-Cell activator with genetic associations to cancer and autoimmunity.
- CD96 and TIGIT are decoy receptors that sequester away CD226's ligand (CD155).
- Inhibition of CD96 leads to immune activation and tumor growth inhibition in non-clinical models.
- GSK6097608 is a high affinity monoclonal antibody against CD96.
- Phase 1 data for GSK6097608 is anticipated in 2022.
- Further clinical development will focus on extending the benefit of GSK'608 in combination with other I/O therapies.
23ME-00610 (P006): A Wholly Owned Immuno-oncology Antibody Targeting CD200R1

Pathway has a strong I/O signature unique to the 23andMe database

CD200 Ligand  CD200R1 Receptor  DOK1 Signaling protein

Cancer  Immune  Cancer

23ME’610 blocks tumor suppression of T cells and activates immune response

CD200 is strongly expressed in a subset of human tumors

Immunohistochemistry for CD200 in Small Cell Lung Cancer

23ME’610 started Phase 1 in January 2022
CD200R1 is an Immunosuppressive Checkpoint in the Presence of CD200

- CD200R1 is an inhibitory receptor expressed on T-cells and myeloid cells
- CD200 is the only known ligand for CD200R1 in humans and is highly expressed on cells within and around the tumor in certain cancers
- Binding of CD200 to CD200R1 decreases the ability of T-cells to recognize and kill cancer cells
- Several viruses, including HHV8 (human herpesvirus-8, which induces Kaposi sarcoma), have co-opted CD200 analogues to suppress and evade the host immune response

CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway.

CD200 is highly expressed in a subset of human cancers.

23ME'610 is a potent, effectorless, monoclonal antibody against CD200R1 that has the potential to restore T-cell killing of cancer cells.

The Phase 1 dose escalation study of 23ME'610 in patients with advanced solid malignancies was initiated in January 2022.

The anticancer efficacy of 23ME'610 will be studied in dose expansion cohorts to determine its optimal dose and schedule for future clinical studies.
We Are Rapidly Scaling Our Therapeutics Discovery Efforts

Cumulative Targets Through Validation

- March 31, 2019: 5
- March 31, 2020: 9
- March 31, 2021: 19
Financials
Strong Financial Foundation to Invest in Future Growth Potential

1. **Investing in future growth potential.** Added telemedicine and online pharmacy to consumer business plus increased spending on Therapeutics R&D by 39% in H1’22 compared to the same period in the prior year.

2. **Growing consumer services and genetic / phenotypic database.** Balancing growth with profitability in Consumer and Research Services supports additional investment in Therapeutics' efforts.

3. **Strong cash position.** Cash of $701 million\(^1\) supports 23andMe’s plans for significant investment in Therapeutics' portfolio and strategic initiatives.

\(^{1}\)As of Sept 30, 2021.
Strategic Investments in Future Growth Potential

FY2022 Guidance

- Revenue: $250 to $260 million
- Net Loss: -$210 to -$225 million
- Adjusted EBITDA: -$143 to -$158 million

1. Excludes the effects of the Lemonaid Health acquisition.
## Income Statement and FY2022 Guidance

1. Excludes the effects of the Lemonaid Health acquisition. Note: Fiscal year ends March 31.

<table>
<thead>
<tr>
<th></th>
<th>Six Months Ended September 30,</th>
<th>Year Ended March 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY2022</td>
<td>FY2021</td>
</tr>
<tr>
<td>(in $M)</td>
<td>Amount</td>
<td>Amount</td>
</tr>
<tr>
<td>Revenue</td>
<td>$114</td>
<td>$100</td>
</tr>
<tr>
<td>Cost of Revenue</td>
<td>55</td>
<td>53</td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td>59</td>
<td>47</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>89</td>
<td>73</td>
</tr>
<tr>
<td>S&amp;M</td>
<td>29</td>
<td>19</td>
</tr>
<tr>
<td>G&amp;A</td>
<td>29</td>
<td>28</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td>147</td>
<td>120</td>
</tr>
<tr>
<td>Income (Loss) from Operations</td>
<td>(88)</td>
<td>(73)</td>
</tr>
<tr>
<td>Other (expense) income</td>
<td>29</td>
<td>1</td>
</tr>
<tr>
<td><strong>Net Income / (Loss)</strong></td>
<td>($59)</td>
<td>($72)</td>
</tr>
<tr>
<td>Adjusted EBITDA (Consolidated)</td>
<td>($57)</td>
<td>($40)</td>
</tr>
</tbody>
</table>
# Revenue Composition

<table>
<thead>
<tr>
<th></th>
<th>Six Months Ended September 30,</th>
<th>Year Ended March 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FY2022</td>
<td>FY2021</td>
</tr>
<tr>
<td>(in $M, except percentages)</td>
<td>Amount</td>
<td>Percentage of Revenue</td>
</tr>
<tr>
<td>Consumer Services</td>
<td>$92</td>
<td>81%</td>
</tr>
<tr>
<td>Research Services</td>
<td>$22</td>
<td>19%</td>
</tr>
<tr>
<td>Therapeutics</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Total</td>
<td>$114</td>
<td>100%</td>
</tr>
</tbody>
</table>
## Consumer Service Revenue Seasonality by Quarter

<table>
<thead>
<tr>
<th></th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Full Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2019</td>
<td>28%</td>
<td>19%</td>
<td>18%</td>
<td>35%</td>
<td>100%</td>
</tr>
<tr>
<td>FY 2020</td>
<td>24%</td>
<td>24%</td>
<td>21%</td>
<td>31%</td>
<td>100%</td>
</tr>
<tr>
<td>FY 2021</td>
<td>18%</td>
<td>21%</td>
<td>22%</td>
<td>39%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Note: Fiscal year ends March 31.
<table>
<thead>
<tr>
<th>(in $M, except percentages)</th>
<th>Amount</th>
<th>Percentage of total R&amp;D expense</th>
<th>Amount</th>
<th>Percentage of total R&amp;D expense</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutics</td>
<td>$42</td>
<td>48%</td>
<td>$30</td>
<td>42%</td>
<td>39%</td>
</tr>
<tr>
<td>Consumer and Research Services</td>
<td>$46</td>
<td>52%</td>
<td>$42</td>
<td>58%</td>
<td>10%</td>
</tr>
<tr>
<td>Total R&amp;D Expense</td>
<td>$89</td>
<td></td>
<td>$73</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Six Months Ended Sept 30, FY2022 vs FY2021*
# Sales and Marketing Expense Composition

<table>
<thead>
<tr>
<th>(in $M)</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advertising and Brand</td>
<td>$16</td>
<td>$5</td>
</tr>
<tr>
<td>Personnel-related expenses</td>
<td>$6</td>
<td>$7</td>
</tr>
<tr>
<td>Outside Services, equipment and supplies</td>
<td>$3</td>
<td>$2</td>
</tr>
<tr>
<td>Facilities and other OH Alloc</td>
<td>$4</td>
<td>$4</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$29</strong></td>
<td><strong>$19</strong></td>
</tr>
</tbody>
</table>
## Segment Information and Reconciliation of Non-GAAP Financial Measures

<table>
<thead>
<tr>
<th>(unaudited)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(in $K)</td>
<td></td>
</tr>
</tbody>
</table>

### Segment Revenue

<table>
<thead>
<tr>
<th>Segment</th>
<th>FY2022</th>
<th>FY2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consumer &amp; Research Services</td>
<td>$114,443</td>
<td>$99,813</td>
</tr>
<tr>
<td>Therapeutics</td>
<td>$48</td>
<td>$48</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>$114,443</strong></td>
<td><strong>$99,861</strong></td>
</tr>
</tbody>
</table>

### Segment Adjusted EBITDA

<table>
<thead>
<tr>
<th>Segment</th>
<th>FY2022</th>
<th>FY2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consumer &amp; Research Services</td>
<td>($1,265)</td>
<td>($2,458)</td>
</tr>
<tr>
<td>Therapeutics</td>
<td>($37,131)</td>
<td>($23,835)</td>
</tr>
<tr>
<td>Unallocated Corporate</td>
<td>($18,563)</td>
<td>($13,757)</td>
</tr>
<tr>
<td><strong>Total Adjusted EBITDA</strong></td>
<td><strong>($56,959)</strong></td>
<td><strong>($40,050)</strong></td>
</tr>
</tbody>
</table>

### Reconciliation of Net Loss to Adjusted EBITDA

<table>
<thead>
<tr>
<th></th>
<th>FY2022</th>
<th>FY2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Loss</td>
<td>($58,550)</td>
<td>($71,961)</td>
</tr>
<tr>
<td>Adjustments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest (income), net</td>
<td>($136)</td>
<td>($143)</td>
</tr>
<tr>
<td>Other (income) expense, net</td>
<td>($17)</td>
<td>($872)</td>
</tr>
<tr>
<td>Change in fair value of warrant liabilities</td>
<td>($29,294)</td>
<td>-</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>$9,508</td>
<td>$16,699</td>
</tr>
<tr>
<td>Stock-based compensation expense</td>
<td>$20,664</td>
<td>$22,227</td>
</tr>
<tr>
<td>Acquisition-related costs</td>
<td>$1,466</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Adjusted EBITDA</strong></td>
<td><strong>($56,959)</strong></td>
<td><strong>($40,050)</strong></td>
</tr>
</tbody>
</table>

**Note:** Fiscal year ends March 31.
Reconciliation of GAAP Net Income Outlook to Non-GAAP Adjusted EBITDA Outlook

<table>
<thead>
<tr>
<th>(unaudited)</th>
<th>Amount</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>(in $M)</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td><strong>Reconciliation of Net Loss to Adjusted EBITDA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Loss²</td>
<td>($225)</td>
<td>($210)</td>
</tr>
<tr>
<td>Adjustments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest (income), net</td>
<td>($0)</td>
<td>($0)</td>
</tr>
<tr>
<td>Other (income) expense, net</td>
<td>$1</td>
<td>$1</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>$19</td>
<td>$19</td>
</tr>
<tr>
<td>Stock-based compensation expense</td>
<td>$47</td>
<td>$47</td>
</tr>
<tr>
<td><strong>Total Adjusted EBITDA</strong></td>
<td>($158)</td>
<td>($143)</td>
</tr>
</tbody>
</table>

We Are Redefining Healthcare. With Data. At Scale.

**Empowering Consumers**

11.9M Genotyped Customers

Enabling **Research & Services**

4B+ Phenotypic Data Points

Developing **Therapeutics**

40+ Programs

**23andMe+**

125K+ Subscribers

**FDA Authorized**

7 FDA Authorizations

**Strong Cash Position**

$701M

---

1As of September 30, 2021. 2As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets.
Appendix
Imputation Allows Us to Make the Vast Majority of GWAS Discoveries at a Fraction of the Cost of Sequencing

Genetic variants are correlated with each other. Knowing the alleles an individual carries at a given position in their genome allows alleles at nearby locations to be inferred.

- This inference process is known as ‘genotype imputation’.

We type ~650,000 SNPs using our genotyping array, which allows accurate imputation for > 35m SNPs in the genome.

Genotype imputation is much more cost effective than whole-genome sequencing.

- Whole-genome sequencing ~$1000 / sample. Exome sequencing ~$400 / sample. Imputation < $0.01 / sample
- We can impute variants down to ~0.5% frequency, which covers the range at which even large GWAS are statistically powered.

We do deploy sequencing in situations where there is a clear benefit over and above imputation.

- E.g. Rare diseases, founder populations, non-European populations, complex regions of the genome, etc.
23andMe’s Value Proposition

**Disrupting the Healthcare experience.** 23andMe is building a personalized health and wellness experience that caters uniquely to the individual by harnessing the power of their DNA. Integrating Lemonaid Health’s online digital health platform to deliver personalized, prevention-oriented, genetically-based healthcare at scale

**The world’s premier re-contactable phenotype-linked genetic database.** A vast (>11M genotyped customers) proprietary dataset rich with both genotypic and phenotypic (health) information allows insights that unlock revenue streams across digital health, therapeutics, and much more

**Continuously increasing quantity and quality of phenotypic data.** Impressive customer participation provides >4 billion phenotypic data points for unprecedented statistical power to discover new insights into health and potential therapies.

**Over 40 identified therapeutics programs validates the approach of developing novel therapeutics using genetic data.** One program in clinical development with GSK, one wholly owned program expected to start clinical trials before end of March 2022.

**Difficult to replicate platform for value creation.** The FDA-approved consumer platform, the therapeutics efforts, and the rich database combine to create multiple opportunities for substantial value creation

**Strong cash position.** Strong balance sheet supports 23andMe’s plans for significant investment in therapeutics portfolio and strategic initiatives